New Data on the Cost of COVID-19 Treatment for U.S. Private Insurers

The COVID-19 pandemic has had an extraordinary, unprecedented, and severe impact on virtually all aspects of life in the United States. The emerging impact of continued virus proliferation on the U.S. health care system will continue to be immense. Wakely Consulting, in a recently released report, updated its March 30, 2020 report on the potential COVID-19 treatment cost implications to U.S. health insurance providers for 2020 and 2021. Since the initial report was published, new data on COVID costs, utilization, and deferred care has become available, and has been incorporated into the update.

The primary changes from the prior report

Leave a Reply